Treatment of Hepatic Encephalopathy With Flumazenil and Change in Cortical GABA Levels in MRS

Withdrawn before enrolling · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Hepatic Encephalopathy, Liver Cirrhosis

In brief

The purpose of this study is to test feasibility of measuring flumazenil-induced changes in cortical GABA levels observed with localized 1H-MRS in relation to changes in severity of hepatic encephalopathy (HE) in subjects with non-alcoholic liver cirrhosis. This study is a double-blind, placebo-controlled, randomized, cross-over design.

Key facts

Study ID
NCT02048969
Run by
Yale University
People needed
0
Starts
2014-06-01
Expected to finish
2017-10-01
Last updated by the study team
2020-07-07

Who can join

Age: 18 and older, up to 99. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.